1. Home
  2. ACRS vs NEXN Comparison

ACRS vs NEXN Comparison

Compare ACRS & NEXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

N/A

Current Price

$3.45

Market Cap

529.9M

Sector

Health Care

ML Signal

N/A

Logo Nexxen International Ltd. American Depository Shares

NEXN

Nexxen International Ltd. American Depository Shares

N/A

Current Price

$8.10

Market Cap

520.5M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ACRS
NEXN
Founded
2012
2007
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
529.9M
520.5M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
ACRS
NEXN
Price
$3.45
$8.10
Analyst Decision
Strong Buy
Buy
Analyst Count
12
9
Target Price
$9.82
★ $14.54
AVG Volume (30 Days)
★ 2.6M
564.2K
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 69.01
N/A
EPS
N/A
★ N/A
Revenue
★ $1,683,000.00
N/A
Revenue This Year
N/A
$9.39
Revenue Next Year
N/A
$9.89
P/E Ratio
★ N/A
$9.64
Revenue Growth
N/A
N/A
52 Week Low
$2.46
$5.60
52 Week High
$6.60
$11.30

Technical Indicators

Market Signals
Indicator
ACRS
NEXN
Relative Strength Index (RSI) 39.18 36.06
Support Level $3.24 $7.06
Resistance Level $4.60 $8.97
Average True Range (ATR) 0.28 0.60
MACD -0.02 -0.06
Stochastic Oscillator 17.03 2.06

Price Performance

Historical Comparison
ACRS
NEXN

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

About NEXN Nexxen International Ltd. American Depository Shares

Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and TV that helps empower advertisers, agencies, digital publishers, broadcasters, and others. The Digital Advertising Ecosystem of the company includes demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. The company operates in America, APAC, EMEA, and Rest of America, with majority revenue from United States.

Share on Social Networks: